Dr. Andrea Rapkin, MD

Dr. Rapkin practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Rapkin's NPI, 1720013485, was assigned on July 11, 2006. Dr. Rapkin graduated from Jacobs School of Medicine and Biomedical Sciences in 1979. Dr. Rapkin holds California license G42583.

Dr. Rapkin's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Rapkin's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Rapkin is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Health Westwood OBGYN. Dmand AI also links Dr. Rapkin to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rapkin practices, 3 sites in all. Vendor and product names are available with a free account.

Obstetrics and gynecology is Dr. Rapkin's primary specialty in the NPI Registry, under taxonomy code 207V00000X. Dr. Rapkin is board certified in obstetrics & gynecology by the American Board of Obstetrics and Gynecology. Dr. Rapkin is licensed in California.

Dmand AI lists menopause, ovarian cyst, UTI and vaginal infection among the conditions Dr. Rapkin treats.

CMS data shows 554 Medicare services from Dr. Rapkin across 8 procedure codes in 2024, for 333 Medicare patients. Medicare paid $31,576 for them. Every service was in an office.

CMS counts 333 Medicare patients who saw Dr. Rapkin in 2024. The largest group is 65 to 74, with 168 patients. 75% of them have high cholesterol, and 60% have arthritis. 10% are also on Medicaid. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rapkin's median patient age at 57, with 99% women.

In 2024, Dr. Rapkin wrote 1,126 Medicare Part D claims for 285 patients. 82% of them were for generic drugs. CMS names the drug for 951 of them, across 27 drugs with 11 or more claims each, at $112,964 in total drug cost. In 2023, CMS named 876 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Rapkin for performance year 2024, reported as part of a group. Dr. Rapkin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rapkin as offering telehealth.

Dmand AI links 22 papers to Dr. Rapkin, published from 2002 to 2021. 2015 was the busiest year, with 4. Dr. Rapkin's most frequent co-authors are Uriel Morav Halbreich, MD, Emeran A. Mayer, MD and David R. Rubinow, MD.

Dmand AI links Dr. Rapkin to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Hirsutism, Tension-Type Headache and Craniomandibular Disorders.

CMS Open Payments shows 31 general payments to Dr. Rapkin from 3 drug and device companies from 2018 to 2024. Speaker and faculty fees make up the largest share, 81% of the total. Abbvie Inc. paid the most, $20,805.

Dmand AI lists 4 awards for Dr. Rapkin, most recently CMS Stage 1 EHR in 2013.

Dr. Rapkin graduated from Jacobs School of Medicine and Biomedical Sciences in 1979. Dr. Rapkin is a member of American College of Obstetricians and Gynecologists.

Dr. Rapkin is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.